Apo-Perindopril · DIN 02289288 · 4mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Perindopril · DIN 02289288
Manufacturer: Apotex Inc.; listing date 2018-04-30
Health Canada: Marketed since 2020-12-18 · brand APO-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Apotex inc · schedule Prescription
Apo-Perindopril: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2042 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77466 · Verify on the e-Formulary ↗ (DIN 02289288)
Source record
DIN 02289288: Apo-Perindopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id APX
Source form: Tab; strength: 4mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2042; ministry $0.2042
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02289288
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77466
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042
Auro-Perindopril · DIN 02459825 · $0.2042
Coversyl · DIN 02123282 · $0.2042
Jamp Perindopril Erbumine · DIN 02527219 · $0.2042
Jamp-Perindopril · DIN 02477017 · $0.2042
M-Perindopril Erbumine · DIN 02482932 · $0.2042
Mar-Perindopril · DIN 02474832 · $0.2042
Mint-Perindopril · DIN 02476770 · $0.2042
NRA-Perindopril · DIN 02489023 · $0.2042
PMS-Perindopril · DIN 02470683 · $0.2042
Perindopril Erbumine · DIN 02479885 · $0.2042
Perindopril Erbumine · DIN 02481642 · $0.2042
Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042
Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: shortage reported ended 2026-06-18 (report last updated 2026-06-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02289288
Shortage record checked 2026-09-13T08:10:21.292534+00:00